Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash from Operations for 7 consecutive years, with 66747000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 8.03% to 66747000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 232891000.0, a 19.74% decrease, with the full-year FY2025 number at 232891000.0, down 19.74% from a year prior.
  • Cash from Operations was 66747000.0 for Q4 2025 at Kymera Therapeutics, down from 27110000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 8045000.0 in Q4 2023 to a low of 79150000.0 in Q1 2025.
  • A 5-year average of 40612450.0 and a median of 39260500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 120.35% in 2023, then crashed 867.98% in 2024.
  • Kymera Therapeutics' Cash from Operations stood at 38352000.0 in 2021, then fell by 3.09% to 39536000.0 in 2022, then surged by 120.35% to 8045000.0 in 2023, then plummeted by 867.98% to 61784000.0 in 2024, then dropped by 8.03% to 66747000.0 in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Cash from Operations are 66747000.0 (Q4 2025), 27110000.0 (Q3 2025), and 59884000.0 (Q2 2025).